Vertex Pharmaceuticals (VX1d)

CBOE (Germany)Healthcare

€389.55
+€13.77 (+3.7%)
Last close

January 21, 2026 at 16:30 UTC

Interactive Chart
VX1d
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About Vertex Pharmaceuticals

Name

Vertex Pharmaceuticals

CEO

Reshma Kewalramani

Industry

Healthcare

Year Founded

1989

Employees

6,100

Vertex Pharmaceuticals is a biotechnology company that discovers, develops, and supplies therapies for serious diseases addressed by targeted approaches. Research is organized around human biology and validated mechanisms, and programs move from early studies to practice with a focus on clear labeling and safe administration. Manufacturing is built for reproducible output and steady availability once a therapy enters routine care. Medical information and field support help clinicians apply guidance without breaking normal workflow. Regional teams manage access within local frameworks, while global functions keep quality and data safeguards aligned. In the healthcare sector and its partner ecosystem, the company positions itself as a long-term supplier that prioritizes continuity for providers and patients.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 4 Buy, 8 Hold, 12 Sell
Buy4
Hold8
Sell12
Fundamentals & Financials
Revenue (TTM)
€11.7B
Net Income (TTM)
€3.6B
EPS (TTM)
€14.32
ROA (TTM)
14.78%
Current Ratio
2.36
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ3 2025
Revenue€3,076.4M
Cost of Sales€414,800K
Gross Profit€2,661.6M
Operating Income€1,186.2M
Net Income€1,082.9M
EPS€4.24
Technical Indicators

Vertex Pharmaceuticals's Technical Indicators Summary

VX1d is currently exhibiting a neutral technical profile, with trend strength remaining subdued as the ADX hovers in a low range, indicating a lack of directional momentum. Momentum indicators present mixed signals: the RSI and MACD suggest consolidation, while the CCI points to some selling pressure. Price is trading below most short- and medium-term moving averages, including the 10- and 50-day SMAs, which are firmly bearish, yet it remains near the 100-day SMA, reflecting some longer-term support. Volatility remains moderate, supported by a stable ATR, and volume trends show mild accumulation with an improving OBV. The instrument is slightly below both the VWAP and classic pivot level, underscoring a balanced tug-of-war between buyers and sellers. Overall, the technical landscape suggests indecision without a clear directional bias.

Buy
4 signals
Neutral
8 signals
Sell
12 signals
Overall: Neutral33% Neutral signals
IndicatorValue
RSI (14)
40.93
Stochastic %K (14, 3, 3)
10.64
CCI (20)
-134.58
WPR (14)
-96.14
Momentum (10)
-22.50
MFI
47.18
MACD Level (12, 26)
0.24
Bollinger Bands
$369.20 - $411.19
ATR (14)
$7.24 (1.93%)
ADX (14)
15.67
OBV
-36,329
VWAP
$375.75
Classic Pivot Point
$378.23
Fibonacci Pivot Point
$378.23
Simple Moving Averages
$363.16 - $392.42(5 indicators)
Exponential Moving Averages
$376.31 - $389.80(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

The day concluded with VX1.DE keeping a mild 0.679% upside gap from yesterday, finishing at roughly 378.20. The session closed with mild sector strength (1.24%), slightly supporting risk appetite. VX1.DE's mild sector strength with limited recent news suggests cautious risk appetite supports the slight gain.

Price Change

from €375.65 close

+€2.55

Trading Volume

Below avg (80)

26

vs S&P 500 Today

Outperforming Market

+1.69%

52-Week Position

Mid-range

39.6%

Updated: January 21, 2026 at 15:45 UTC

Quote Summary
OpenPrevious Close
€376.45€375.65
Day Range52 Week Range
€376.45 - €378.2€312.65 - €478.1
VolumeAvg. Volume
2696
Market CapP/E Ratio
€97.2B31.0